The company has posted net loss of $7.74m, or $0.43 loss per diluted share, as compared to net loss of $9.15m, or $0.62 loss per diluted share, for the year ago period.
Spherix’s loss from operations was $8.01m for the fiscal year ended 31 December 2010, compared to the loss from operations of $9.15m.
Spherix CEO Claire Kruger said they have begun a human clinical postprandial trial with Dtagatose in the treatment of high triglycerides and data from this human trial are expected to be announced in the fall of 2011.